ExonHit Therapeutics, a drug and diagnostic discovery company, today announces that it has filed a patent with the French Intellectual Property Institute (INPI) which covers a panel of genes that could enable the differential diagnosis of Alzheimer's patients from blood. The use of these genes will allow the identification of patients suffering from Alzheimer's disease from a population of elderly patients with no signs of cognitive disorders.
